ArticleThe oncologist2026
Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) health disparities are well-documented, with non-Hispanic Black (NHB) and male individuals experiencing higher disease burdens than their non-Hispanic White (NHW) or female counterparts. However, no studies have shown that how these disparities translate into differences in life expectancy, particularly for monoclonal gammopathy of undetermined significance (MGUS), a precursor to MM. This study quantified the remaining life years and life years lost associated with MGUS and MM to inform MM prevention and control priorities.
methodsWe developed a discrete-event simulation (DES) model of the natural history of MM, calibrated using nationally representative data on serologic-detected MGUS and registry-based MM. The model was stratified by race and gender (NHB/NHW men and women). Life years lost was computed as the difference in life years between populations without and with MGUS/MM.
resultsRemaining life years for MGUS/MM were 17.8/6.3 (95% prediction interval [PI]: 17.4-18.2/5.9-6.9) for NHB men, 20.1/7.7 (95% PI: 19.7-20.5/7.1-8.3) for NHB women, 20.9/7.3 (95% PI: 20.3-21.4/6.7-8.0) for NHW men, and 23.0/8.5 (95% PI: 22.5-23.6/7.7-9.4) for NHW women. Corresponding life years lost associated with MGUS/MM was 7.6/14.2 (95% PI: 7.3-8.0/13.3-15.1), 8.0/16.0 (95% PI: 7.7-8.4/15.0-17.0), 8.4/16.0 (95% PI: 8.0-8.9/14.7-17.3), and 8.8/18.1 (95% PI: 8.4-9.2/16.9-19.4), respectively.
conclusionSubstantial racial and gender differences were identified and quantified in disease burden associated with MGUS and MM, which provides concrete targets for MM prevention and control efforts. Our findings underscore the need for tailored strategies to reduce MM disparities, for example, enhancing disease monitoring among NHB populations and improving treatment adherence among men with MM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.